MDM2 and cancer: Therefore, for leveraging p53 activation as a cancer therapy, it is crucial to identify compound combinations that reduce the dosage of MDM2 inhibitors needed, while also enhancing their capacity to induce cell death rather than inducing reversible cell cycle arrest [127].